

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
VIRTUAL PLATFORM**

April 21, 2021

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of meeting transcript for January 20, 2021 meeting
- IV. Review of draft meeting summary for January 20, 2021 meeting
- V. Secretary's report
- VI. Old Business
 - A. United Healthcare breakdown of denials in PA report
- VII. New Business
 - A. Proposed protocol for Korlym® (mifepristone)
 - B. Proposed protocol for Juxtapid® (Iomitapide)
 - C. Proposed protocol for Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) products
- VIII. A. Informational Highlights/Reports
 1. DXC Technology/NJ HMO 4th Quarter 2020 Prior Authorization Report
 2. Summary of DURB Action Items
 3. (a) DHS, DHSS and MCO Programs Top Drugs Report/Physicians Administered Drugs (by amount paid and by category)
(b) Antiviral drugs by amount paid

B. Medication information:

 1. COVID-19 Vaccines information
<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines>
 2. Information for Clinicians on Investigational Therapeutics for Patients with COVID-19
<https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html>
 3. New Jersey COVID-19 Information Hub
<https://covid19.nj.gov/>
 4. Monoclonal Antibody Therapy for COVID-19 in New Jersey
<https://www.northjersey.com/story/news/coronavirus/2021/01/29/test-positive-covid-high-risk-mono-clonal-antibodies-may-help/4244158001/> [Source: northjersey.com]
- IX. Referenced Materials:
 1. Addendum to Opioid protocol – criterion #7
 2. Exclusion protocol for Victoza – change of word “limitations” to “exclusions”